Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Long-Term Liabilities (Tables)

v3.8.0.1
Accrued Expenses and Other Long-Term Liabilities (Tables)
3 Months Ended
Mar. 31, 2018
Components of Accrued Expenses and Other Long-Term Liabilities
Accrued expenses and other long-term liabilities, excluding National, consisted of the following:
 
 
 
March 31, 
2018
 
December 31,
2017
 
Accrued expenses:
 
 
 
 
 
 
 
Professional fees
 
$
1,497
 
$
1,625
 
Salaries, bonuses and related benefits
 
 
6,002
 
 
5,279
 
Accrued expenses - related party
 
 
107
 
 
95
 
Research and development
 
 
7,061
 
 
4,046
 
Dr. Falk Pharma milestone (See Note 16)
 
 
3,059
 
 
3,059
 
Accrued royalties payable
 
 
1,091
 
 
1,411
 
Accrued coupon expense
 
 
735
 
 
–
 
Deferred coupon funding
 
 
1,516
 
 
1,087
 
Other
 
 
646
 
 
1,030
 
Total accrued expenses
 
$
21,714
 
$
17,632
 
 
 
 
 
 
 
 
 
Other long-term liabilities:
 
 
 
 
 
 
 
Deferred rent
 
 
4,759
 
 
4,739
 
Total other long-term liabilities
 
$
4,759
 
$
4,739
 
National Holdings Corporation [Member]  
Components of Accrued Expenses and Other Long-Term Liabilities
National's accounts payable and other accrued expenses as of December 31, 2017 and September 30, 2017, consisted of the following:
 
 
 
December 31,
 
September 30,
 
 
 
2017
 
2017
 
Legal
 
$
653
 
$
877
 
Audit
 
 
171
 
 
176
 
Telecommunications
 
 
208
 
 
205
 
Data Services
 
 
454
 
 
464
 
Regulatory
 
 
663
 
 
540
 
Settlements
 
 
1,789
 
 
2,403
 
Deferred rent
 
 
684
 
 
497
 
Other
 
 
3,437
 
 
3,242
 
Total
 
$
8,059
 
$
8,404